Patent application number | Description | Published |
20090118249 | DHEAS INHALATION COMPOSITIONS - The present invention provides compositions for aqueous suspension comprising DHEAS and a divalent cation. The suspension in combination with a nebulizer or nasal pump spray can be administers as an aerosol for the treatment of respiratory diseases and conditions. The present invention also provides methods for making compositions in form of aqueous suspension of DHEA and divalent cations. | 05-07-2009 |
20090232744 | Macrolide compositions having improved taste and stability - The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability. | 09-17-2009 |
20090304604 | PULMONARY DELIVERY OF ALPHA-1 PROTEINASE INHIBITOR - The present invention relates to a system that includes a pharmaceutical composition of a purified, stable, active alpha-1 proteinase inhibitor (API) in a form of a ready to use sterile solution and an inhalation nebulizer, and to methods of use thereof for treating pulmonary diseases. | 12-10-2009 |
20100316576 | AEROSOLS FOR SINUNASAL DRUG DELIVERY - A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterised in that it exhibits a low effective flow rate of less than about 5 litres per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis. | 12-16-2010 |
20120211005 | PULMONARY DELIVERY OF ALPHA-1 PROTEINASE INHIBITOR - The present invention relates to a system that includes a pharmaceutical composition of a purified, stable, active alpha-1 proteinase inhibitor (API) in a form of a ready to use sterile solution and an inhalation nebulizer, and to methods of use thereof for treating pulmonary diseases. | 08-23-2012 |
20130177626 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLOSPORIN - The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol. | 07-11-2013 |
20140343005 | AQUEOUS COMPOSITIONS COMPRISING ARBEKACIN - The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory tract, wherein the composition is aerosolized and inhaled by the patient. Furthermore, the invention provides arbekacin hydrochloride. | 11-20-2014 |
20140366872 | AEROSOLS FOR SINUNASAL DRUG DELIVERY - A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterised in that it exhibits a low effective flow rate of less than about 5 litres per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis. | 12-18-2014 |